Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N‐terminal pro‐brain natriuretic peptide

摘要

Objective Our study was to explore the roles between serum soluble suppression of tumorigenicity 2 (sST2) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) while evaluating ventricular function to properly diagnose chronic heart failure (CHF). Methods In total, 197 CHF patients were recruited and classified into ventricular function's II, III, and IV groups, and 106 healthy people into normal control group. To detect concentrations of Sst2 and NT‐proBNP, ELISA and electro‐chemiluminescence immuno assay were implemented. An automatic biochemical analyzer was used to determine the levels of the following: blood urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), triglyceride (TG), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), and uric acid (UA). A receiver operating characteristic (ROC) curve was adopted to detect the diagnostic value sST2 and NT‐ProBNP in CHF and the logistic regression analysis involving the risk factors of CHF. Results Serum sST2 and NT‐proBNP concentrations were increased significantly in the ventricular function's II, III, and IV groups in a manner dependent on concentration as opposed to the manner the normal control group occupied. The area under the curve (AUC) of sST2, found NT‐proBNP and sST2+NT‐proBNP to be 0.942 (95% CI: 0.917‐0.966), 0.920 (95% CI: 0.891‐0.948), and 0.968 (95% CI: 0.953‐0.984), respectively. sST2, NT‐proBNP, UA, and Cr were verified as important risk factors of CHF. Conclusion Serum sST2 and NT‐ProBNP could act as diagnostic indicators for CHF.